Carotuximab (also known as TRC105) is an investigational chimeric monoclonal antibody developed as an anti-angiogenic agent for the treatment of solid tumors. It is designed to inhibit the formation of new blood vessels that supply tumors with oxygen and nutrients. Clinical trials have evaluated its efficacy, both as a monotherapy and in combination with other anti-cancer therapies such as VEGF inhibitors or chemotherapy, in a range of advanced cancers including soft tissue sarcoma, hepatocellular carcinoma, mesothelioma, and glioblastoma. However, its development has faced challenges, and it has not yet achieved widespread regulatory approval for clinical use.